Amnestic Mild Cognitive Impairment Clinical Trial
Official title:
Using Artificial Intelligence to Predict Cognitive Training Response in Amnestic Mild Cognitive Impairment
This study will train a machine learning tool to predict response to a cognitive training intervention using baseline brain MRI sequences from older adults with amnestic mild cognitive impairment.
Status | Recruiting |
Enrollment | 75 |
Est. completion date | April 30, 2028 |
Est. primary completion date | April 30, 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years to 100 Years |
Eligibility | Inclusion Criteria: - Evidence of changed cognition reported by a close informant as obtained by an interview with a licensed clinical psychologist (PI, Gullett) - Cognitive performance on one or more standardized neuropsychological measures of verbal or non-verbal memory > 1.0 standard deviation or more below the normative mean for age and education - No evidence of reported dependence in instrumental functional abilities (IADLs) despite reported cognitive difficulties - No evidence of dementia based on cognitive screening (Montreal Cognitive Assessment Score within normal limits for age, education, and sex using the NACC Uniform Data Set (UDS) norms. - Global clinical dementia rating scale (CDR) score must be equal to 0.5 - Willingness to be randomized into either the educational training (control) or intervention (cognitive training) group - Able and willing to devote 12 weeks to the intervention with additional time for pre- and post-testing - Able and willing to perform cognitive and emotional measures both on paper and on a tablet computer - In line with the recommendations of the SCD task force, an informant must be available. This is to a) obtain information about the participant's complaints and cognitive difficulties on interview, and b) to ascertain validity of self-reported IADL function in regard to instrumental functional activities. Exclusion Criteria: - Sensory loss (vision, hearing) or motor deficits that would preclude participation in the experimental tasks or neuropsychological assessment - English as a second language - Inability to undergo brain imaging due to claustrophobia or implants such as pacemakers, heart valves, brain aneurysm clips, orthodontics, non-removable body jewelry, or shrapnel containing ferromagnetic metal - Previous major strokes or other known significant brain abnormalities or diseases affecting the brain and/or cognition (e.g., Parkinson disease, multiple sclerosis, seizure disorder, brain surgery, moderate TBI, REM Behavior Sleep Disorder, untreated sleep apnea, etc.) - Unstable and uncontrolled medical conditions (metastatic cancer, HIV, moderate-severe kidney disease, uncontrolled diabetes, uncontrolled hypertension, severe cardiac disease, etc.). No current cancer diagnosis - Current or past history of major psychiatric disturbance including schizophrenia, or active psychosis, bipolar disorder, current major depressive episode, current alcohol or substance abuse or history thereof within the past six months. The investigators are not excluding individuals who are taking antidepressant or anti-anxiety medications, however, use of these medications will be recorded and data analyzed in post-hoc analyses - Use of antipsychotics, sedatives, or other medications with significant anticholinergic properties (due to potential influence on memory) - Use of photo-sensitive medications such as steroids or retin-A within 15 days of the study intervention. - Previous participation in a cognitive training study within the last 6 months or current involvement in another study involving cognitive, physical or other intervention at the time of participation. |
Country | Name | City | State |
---|---|---|---|
United States | University of Florida | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Florida | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Useful Field of View Composite | The Useful Field of View (UFOV) composite change score is calculated by subtracting the post-intervention score (0-500) from the pre-intervention score (0-500), where a more negative change score is indicative of stronger improvement after intervention (range +500 to -500). | Baseline up to week 12 during follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01525368 -
Outcome Predictors of a Cognitive Intervention in aMCI
|
N/A | |
Completed |
NCT00785759 -
Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers
|
Phase 2 | |
Completed |
NCT02562989 -
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
|
Phase 1 | |
Completed |
NCT02910739 -
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
|
Phase 1 | |
Completed |
NCT04185298 -
mSIM: Mobile Simultaneous Aerobic Exercise and Memory Training Intervention for Amnestic Mild Cognitive Impairment
|
N/A | |
Not yet recruiting |
NCT04103463 -
Interactive Stepping Exercise on Memory
|
N/A | |
Recruiting |
NCT04063956 -
COG-REAGENT: COGnitive tRaining in patiEnts With Amnestic Mild coGnitive impairmENT
|
N/A | |
Terminated |
NCT01953601 -
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
|
Phase 3 | |
Recruiting |
NCT06041152 -
Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment
|
Phase 2 | |
Completed |
NCT01962038 -
A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT06444568 -
Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments
|
N/A | |
Recruiting |
NCT03133052 -
CTA-MCI: Cognitive Control Training in Patients With Amnestic Mild Cognitive Impairment(CTA-MCI)
|
N/A | |
Not yet recruiting |
NCT05987007 -
Sleep Interventions and Neurocognitive Outcomes
|
N/A | |
Recruiting |
NCT04240561 -
Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia
|
N/A | |
Completed |
NCT01767909 -
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
|
Phase 2/Phase 3 | |
Terminated |
NCT01072812 -
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
|
Phase 1 | |
Completed |
NCT00643266 -
Recollection Training in Healthy Older Adults and Older Adults With Amnestic Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT04504630 -
Noninvasive Brain Stimulation on Memory in Individuals With Mild Cognitive Impairment and History of Brain Injury
|
N/A | |
Terminated |
NCT00582855 -
Effect of AQW051 in Patients With Memory Impairment
|
Phase 2 | |
Recruiting |
NCT05446584 -
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
|
Phase 2 |